vidarabine has been researched along with Smith-Magenis Syndrome in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S | 1 |
| Jain, N | 1 |
| Bulian, P; Cerri, M; Chiarenza, A; Cortelezzi, A; Coscia, M; Cuneo, A; De Paoli, L; Del Giudice, I; Del Poeta, G; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Gentile, M; Ghilardi, G; Laurenti, L; Marasca, R; Massaia, M; Mauro, FR; Montillo, M; Morabito, F; Moreno, C; Motta, M; Neri, A; Perbellini, O; Rigolin, GM; Rossi, D; Tedeschi, A; Terzi-di-Bergamo, L; Vincelli, I; Visco, C; Zaja, F; Zinzani, PL | 1 |
| Badoux, XC; Burger, J; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, SM; Wang, X; Wierda, WG | 1 |
| Badoux, X; Burger, J; Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Parikh, SA; Wang, X; Wierda, WG | 1 |
1 review(s) available for vidarabine and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
3 trial(s) available for vidarabine and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Smith-Magenis Syndrome; Survival Rate; Vidarabine | 2015 |
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Salvage Therapy; Smith-Magenis Syndrome; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2011 |
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Risk Factors; Rituximab; Smith-Magenis Syndrome; Thrombocytopenia; Vidarabine | 2011 |
1 other study(ies) available for vidarabine and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2020 |